| scholarly article | Q13442814 |
| P50 | author | Loreto Carmona | Q56419499 |
| P2093 | author name string | Dolores Ruiz-Montesinos | |
| Eva Perez-Pampin | |||
| Juan J Gómez-Reino | |||
| Alba Erra | |||
| BIOBADASER and EMECAR Groups | |||
| Miguel Angel Descalzo | |||
| Tatiana Cobo | |||
| P2860 | cites work | Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity | Q24673967 |
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients | Q33562682 | ||
| Invited commentary: propensity scores | Q33715877 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| Coronary artery disease and rheumatoid arthritis | Q34531168 | ||
| Side effects of anti-TNF therapy: current knowledge. | Q35015432 | ||
| Infections and biological therapy in rheumatoid arthritis | Q35145540 | ||
| Mortality in rheumatoid arthritis patients with disease onset in the 1980s | Q35548197 | ||
| No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset | Q35549071 | ||
| Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study | Q35551075 | ||
| Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists | Q35554865 | ||
| Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s | Q35554980 | ||
| Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. | Q35579309 | ||
| Infections and anti–tumor necrosis factor α therapy | Q35581950 | ||
| Rheumatoid arthritis registries in Sweden. | Q36307644 | ||
| Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 | ||
| Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis | Q40525673 | ||
| Infliximab: additional safety data from an open label study. | Q42674122 | ||
| Accuracy of death certificates for coding coronary heart disease as the cause of death | Q43891160 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis | Q45069605 | ||
| Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report | Q45180236 | ||
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists | Q46525959 | ||
| Rheumatoid arthritis and accelerated atherogenesis | Q47266077 | ||
| Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody | Q47368581 | ||
| Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. | Q47997659 | ||
| Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. | Q50701881 | ||
| Increased risk of tuberculosis in patients with rheumatoid arthritis. | Q50722426 | ||
| Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. | Q50881711 | ||
| Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. | Q50969877 | ||
| Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. | Q53558225 | ||
| Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. | Q54193569 | ||
| Is the apparent rise in cancer mortality in the elderly real? analysis of changes in certification and coding of cause of death in England and Wales, 1970–1990 | Q62583522 | ||
| Mortality in rheumatoid arthritis | Q71125278 | ||
| Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina | Q72711416 | ||
| Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset | Q73292550 | ||
| Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis | Q73374692 | ||
| Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects | Q73628316 | ||
| Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity | Q73782535 | ||
| Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta down-regulate intercellular adhesion molecule (ICAM)-2 expression on the endothelium | Q77386394 | ||
| High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 | ||
| Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease | Q79354392 | ||
| Infectious causes of death in patients with rheumatoid arthritis: an autopsy study | Q80043632 | ||
| Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| TNF | Q18032037 | ||
| P304 | page(s) | 880-885 | |
| P577 | publication date | 2007-02-26 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists | |
| P478 | volume | 66 |
| Q26829931 | A meta-analysis of mortality in rheumatic diseases |
| Q38183297 | A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis |
| Q33687843 | Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis |
| Q37404893 | Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases |
| Q36677345 | Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease |
| Q38238948 | Adverse reactions to biologic agents and their medical management. |
| Q33602465 | Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database |
| Q36590690 | Association between anti-TNF-α therapy and all-cause mortality |
| Q46635567 | Automated radiofrequency-based US measurement of common carotid intima-media thickness in RA patients treated with synthetic vs synthetic and biologic DMARDs. |
| Q33529391 | Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database |
| Q85069915 | Biologics and cardiovascular risk |
| Q33898103 | Biologics and heart failure in rheumatoid arthritis: are we any wiser? |
| Q36835851 | Cardiovascular co-morbidity in rheumatic diseases |
| Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
| Q30240180 | Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q36361147 | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs |
| Q64103936 | Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis |
| Q36901936 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. |
| Q40961450 | Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis |
| Q84311215 | Decreased heart rate variability in patients with psoriatic arthritis |
| Q41581523 | Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach |
| Q37838346 | Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents |
| Q37774304 | Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality |
| Q52841141 | Etanercept in the treatment of rheumatoid arthritis. |
| Q37479670 | How safe are the biologicals in treating asthma and rhinitis? |
| Q42359937 | Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention |
| Q24653374 | Immunotoxicity of monoclonal antibodies |
| Q30494937 | Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study |
| Q33346685 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence |
| Q36182351 | Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis |
| Q37975943 | Managing cardiovascular risk in patients with chronic inflammatory diseases. |
| Q45755289 | Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. |
| Q34658023 | Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab |
| Q47272022 | Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register |
| Q34699641 | No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register |
| Q44553220 | No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan |
| Q33478325 | Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study |
| Q39371679 | Pathogenetic insights from the treatment of rheumatoid arthritis |
| Q28709376 | Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis |
| Q35617617 | Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label |
| Q45669904 | Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis |
| Q37632485 | Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review |
| Q40552131 | Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients |
| Q40000074 | Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan |
| Q30240183 | Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. |
| Q41176187 | Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides |
| Q35705082 | Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review |
| Q30731527 | Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. |
| Q47687376 | Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
| Q37907921 | Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence |
| Q26852081 | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
| Q51176752 | Stakeholder Satisfaction with the Australian Rheumatology Association Database (ARAD). |
| Q57956172 | Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) über Fälle von Malignomen bei Anti-TNF-behandelten Patienten |
| Q49218023 | Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial |
| Q37801353 | Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis |
| Q41211836 | The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease risk index is better than SCORE and QRisk II in rheumatoid arthritis: is it enough? |
| Q35135831 | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. |
| Q38420988 | The epidemiology of rheumatoid arthritis in Ontario, Canada |
| Q35092457 | The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. |
| Q37974121 | The practical value of biologics registries in Africa and Middle East: challenges and opportunities |
| Q33892790 | The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study |
| Q33743130 | The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality |
| Q38755133 | The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis |
| Q35557863 | Treating rheumatic patients with a malignancy |
| Q30680371 | Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data |
| Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
| Q38416583 | Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada |
| Q36806922 | Tumor necrosis factor inhibitors and infection complications |
| Q37808889 | Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
| Q26822912 | Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis |
| Q34818636 | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| Q37290628 | Update on the use of etanercept across a spectrum of rheumatoid disorders |
Search more.